Abstract:
본 발명은 3,4-다이메틸렌옥세페인 화합물과 이의 제조방법에 관한 것으로서, 더욱 상세하게는 알렌닐 알코올 화합물과 알데하이드 화합물을 특정의 루이스산과 특정의 용매 존재하에서 프린스 고리화 반응을 수행하여 제조된, 입체선택성을 가지는 하기 화학식 1로 표시되는 3,4-다이메틸렌옥세페인 화합물과 이 화합물의 제조방법에 관한 것이다. [화학식 1]
상기 화학식 1에서, R 1 은 수소원자; C 1-6 알킬기; 또는 페닐기를 나타내고, R 2 는 C 1-6 알킬기; 할로, 나이트로, C 1-6 알킬, 및 C 1-6 알콕시 중에서 선택된 1 내지 3개의 치환기로 치환 또는 비치환된 페닐기; 퓨란일기; 또는 티오펜일기를 나타낸다.
Abstract:
PURPOSE: A pharmaceutical composition containing 1,4-diazepane pyrazole compound and a pharmaceutically acceptable salt thereof is provided to be used as an agent for preventing or treating brain diseases, heart diseases, cancer, epilepsy, and pain. CONSTITUTION: A 1,4-diazepane pyrazole compound is denoted by chemical formula 1. A pharmaceutical composition for preventing and treating brain diseases such as epilepsy, depression, Parkinson's diseases, dementia, sleep disorders, or heart diseases such as hypertension, cardiac arrhythmia, or myocardial infarction, or pain contains the compound of chemical formula 1 as an active ingredient. A method for preparing the compound of chemical formula 1 comprises a step of reacting pyrazolemethyl amine of chemical formula 2 with chloroacetyl chloride.
Abstract:
PURPOSE: A pharmaceutical composition containing pyrazoyl piperidine compounds and pharmaceutically acceptable salt thereof is provided to prevent or treat brain diseases, heard diseases, cancer, and pain. CONSTITUTION: A pyrazoyl piperidine compound is denoted by chemical formula 1. A pharmaceutical composition for treating cerebral diseases, cardiac diseases, cancer, or pain contains the compound of chemical formula 1 as an active ingredient. A method for preparing the compound comprises: a step of reacting piperidine acetate of chemical formula 2 and pyrazole methyl amine of chemical formula 3 of a step of reacting piperidine compound of chemical formula 4 with an aldehyde compound of chemical formula 5 by reduction-amination. [Reference numerals] (AA) Reductive amination
Abstract:
본 발명은 세로토닌 수용체 억제 작용과 세로토닌 트랜스포터 (Serotonin transporter)에 대한 억제 작용을 동시에 가지는 설폰아마이드 화합물과 이의 약제학적으로 허용 가능한 염에 관한 것이다. 본 발명이 특징으로 하는 설폰아마이드 화합물은 세로토닌 5-HT 2A 수용체 길항 작용과 세로토닌 트랜스포터 억제 작용을 가지므로 우울증, 비만, 정신병(psychosis), 정신분열증, 자살성향(suicidal tendency), 불안증(anxiety), 강박노이로제, 편두통, 식욕부진(appetite disorders), 수면장애(sleep disorders), 발작, 약물남용에 의한 금단증상 등 중추신경계(CNS)에 관련된 질환의 예방 및 치료제로 유용하다. 설폰아마이드 화합물, 세로토닌, 5-HT2A/5-HT2C, SSRI, 중추신경계, 우울증, 비만
Abstract:
본 발명은 하기 화학식 1로 표시되는 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 T-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물에 관한 것으로, 본 발명에 따른 페닐아세테이트 유도체를 함유하는 조성물은 T-형 칼슘 이온 채널 활성을 효과적으로 억제하므로 T-형 칼슘 이온 채널의 활성에 의해 유발되는 고혈압, 암, 간질, 신경성 통증 등의 질병의 예방 또는 치료제로서 유용하게 사용될 수 있다. [화학식 1] . (상기 화학식 1에서, 상기 X, R 1 및 R 2 는 본 명세서에서 정의된 바와 같다.) T-형 칼슘 채널 블로커, 페닐아세테이트 유도체, 통증치료제
Abstract:
PURPOSE: A method for preparing 1,6-dioxecane compound is provided to enlarge other ring by Diels-Alder reaction and to use as an intermediate. CONSTITUTION: A 1,6-Dioxecanes compound is denoted by chemical formula 1. The 1,6-Dioxecanes compound is prepared by Prins reaction of alcohol compound of chemical formula 2 and aldehyde compound of chemical formula 3. A tetrahydrofuran is used as a reaction catalyst. The reaction temperature is -78 to 30°C.
Abstract:
PURPOSE: A thiazoline compounds and a T-type calcium channel inhibitor containing the same are provided to treat diseases relating to T-type calcium channel overexpression. CONSTITUTION: A thiazoline compounds have a structure of chemical formula 1. A composition for preventing and treating diseases relating to T-type calcium channel overexpression contains the thiazoline compounds of chemical formula 1. The diseases are Parkinson's disease, Alzheimer, schizophrenia, somnopathy, pain, hypertension, arrhythmia, angina, cardiac insufficiency, myocardial infarction, or cancer.
Abstract:
PURPOSE: A novel phenylacetate derivative and a composition containing the same are provided to suppress T-type calcium ion channel activity and to use as a therapeutic agent for preventing or treating diseases caused by T-type calcium ion channel activity. CONSTITUTION: A phenylacetate derivative is denoted by chemical formula 1. A method for preparing the phenylacetate derivative comprises: a step of performing esterification of a carboxylic acid compound of chemical formula 2 under acid catalyst to obtain an ester compound of chemical formula 3; a step of reacting the compound of chemical formula 3 with t-butoxide and isopropyl bromide to obtain a compound of chemical formula 4; a step of reacting the compound of chemical formula 4 with 1,3-dibromopropane to obtain a compound of chemical formula 5; and a step of reacting the compound of chemical formula 5 with a compound of chemical formula 6 or 7.